Colorectal Cancer
Copyright ©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 28, 2006; 12(12): 1849-1858
Published online Mar 28, 2006. doi: 10.3748/wjg.v12.i12.1849
Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: The Freiburg experience (1989-2002)
Christian Weissenberger, Michael Geissler, Florian Otto, Annette Barke, Karl Henne, Georg von Plehn, Alex Rein, Christine Müller, Susanne Bartelt, Michael Henke
Christian Weissenberger, Department of Radiotherapy, University Hospital of Freiburg, 79106 Freiburg, Germany
Michael Geissler, Department Oncology, Gastroenterology and Internal Medicine, Städtische Kliniken Esslingen, 73730 Esslingen a. N., Germany
Florian Otto, Department of Internal Medicine I, Division of Oncology, University Hospital of Freiburg, 79106 Freiburg, Germany
Annette Barke, Henne Karl, von Plehn Georg, Rein Alex, Müller Christine, Bartelt Susanne, Henke Michael, Department of Radiotherapy, University Hospital of Freiburg, 79106 Freiburg, Germany
Correspondence to: Dr. Christian Weissenberger, Department of Radiotherapy, University Hospital of Freiburg, 79106 Freiburg, Germany. weissenb@mst1.ukl.uni-freiburg.de
Telephone: +49-761-2709401 Fax: +49-761-2709582
Received: September 12, 2005
Revised: October 2, 2005
Accepted: October 26, 2005
Published online: March 28, 2006
Abstract

AIM: To evaluate the long-term outcome of standard 5-FU based adjuvant or neoadjuvant radiochemotherapy and to identify the predictive factors, especially anemia before and after radiotherapy as well as hemoglobin increase or decrease during radiotherapy.

METHODS: Two hundred and eighty-six patients with Union International Contre Cancer (UICC) stage II and III rectal adenocarcinomas, who underwent resection by conventional surgical techniques (low anterior or abdominoperineal resection), received either postoperative (n = 233) or preoperative (n = 53) radiochemotherapy from January 1989 until July 2002. Overall survival (OAS), cancer-specific survival (CSS), disease-free survival (DFS), local-relapse-free (LRS) and distant-relapse-free survival (DRS) were evaluated using Kaplan-Meier, Log-rank test and Cox’s proportional hazards as statistical methods. Multivariate analysis was used to identify prognostic factors. Median follow-up time was 8 years.

RESULTS: Anemia before radiochemotherapy was an independent prognostic factor for improved DFS (risk ratio 0.76, P = 0.04) as well as stage, grading, R status (free radial margins), type of surgery, carcinoembryonic antigen (CEA) levels, and gender. The univariate analysis revealed that anemia was associated with impaired LRS (better local control) but with improved DFS. In contrast, hemoglobin decrease during radiotherapy was an independent risk factor for DFS (risk ratio 1.97, P = 0.04). During radiotherapy, only 30.8% of R0-resected patients suffered from hemoglobin decrease compared to 55.6% if R1/2 resection was performed (P = 0.04). The 5-year OAS, CSS, DFS, LRS and DRS were 47.0%, 60.0%, 41.4%, 67.2%, and 84.3%, respectively. Significant differences between preoperative and postoperative radiochemotherapy were not found.

CONCLUSION: Anemia before radiochemotherapy and hemoglobin decrease during radiotherapy have no predictive value for the outcome of rectal cancer. Stage, grading, R status (free radial margins), type of surgery, CEA levels, and gender have predictive value for the outcome of rectal cancer.

Keywords: Rectal cancer; Adjuvant radiotherapy; Adjuvant radiochemotherapy; Anemia; Prognostic factor